Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Li, Jingmei ^a   Czene, Kamila ^b   Brauch, Hiltrud ^c   Schroth, Werner ^c   Saladores, Pilar ^c   Li, Yi ^a   Humphreys, Keith ^b   Hall, Per ^b  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; ENZYME POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHIC DENSITY; MAMMOGRAPHY; QUANTITATIVE TRAIT; TREATMENT RESPONSE; BREAST TUMOR; CONGENITAL MALFORMATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; MAMMARY GLAND; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MAMMARY GLANDS, HUMAN; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84884842772     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3495     Document Type: Article

References (29)

1. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282. 10.1093/jnci/djk049, 17312304.
2. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784. 3163848, 21802721.
3. Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, Han SW, Im SA, Kim TY, Koo HR, Chang JM, Cho N, Moon WK, Noh DY. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 2012, 14:R102. 10.1186/bcr3221, 3680951, 22770227.
4. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011, 103:744-752. 10.1093/jnci/djr079, 21483019.
5. Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol 2013, 31:2249-2256. 10.1200/JCO.2012.44.5015, 23610119.
6. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008, 83:160-166. 10.1038/sj.clpt.6100367, 2752373, 17882159.
7. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436. 10.1001/jama.2009.1420, 19809024.
8. Magnusson C, Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, Adami HO. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer 1998, 76:29-34. 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.0.CO;2-#, 9533758.
9. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999, 81:339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6, 10209946.
10. Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R, Adami HO. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer 1999, 80:231-236. 10.1002/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.0.CO;2-R, 9935204.
11. Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, Persson I, Baron J, Weiderpass E. Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004, 6:R437-R449. 10.1186/bcr811, 468663, 15217512.
12. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol 1994, 145:1301-1308. 1887491, 7992835.
13. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009, 24:659-667. 10.1007/s10654-009-9350-y, 2773709, 19504049.
14. Li J, Szekely L, Eriksson L, Heddson B, Sundbom A, Czene K, Hall P, Humphreys K. High-throughput mammographic-density measurement: a tool for risk prediction of breast cancer. Breast Cancer Res 2012, 14:R114. 10.1186/bcr3238, 3680940, 22846386.
15. Chen JH, Nie K, Bahri S, Hsu CC, Hsu FT, Shih HN, Lin M, Nalcioglu O, Su MY. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation. Radiology 2010, 255:44-52. 10.1148/radiol.09091090, 2843830, 20308443.
16. Buckley JH, Roebuck EJ. Mammographic changes following radiotherapy. Br J Radiol 1986, 59:337-344. 10.1259/0007-1285-59-700-337, 3697610.
17. Kuzmiak CM, Zeng D, Cole E, Pisano ED. Mammographic findings of partial breast irradiation. Acad Radiol 2009, 16:819-825. 10.1016/j.acra.2009.01.021, 19375948.
18. R Development Core Team R: A language and environment for statistical computing 2008, Vienna, Austria: R Foundation for Statistical Computing, R Development Core Team.
19. Osborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 2000, 60:3706-3712.
20. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012, 104:1266-1268.
21. Kelemen LE, Pankratz VS, Sellers TA, Brandt KR, Wang A, Janney C, Fredericksen ZS, Cerhan JR, Vachon CM. Age-specific trends in mammographic density: the Minnesota breast cancer family study. Am J Epidemiol 2008, 167:1027-1036. 10.1093/aje/kwn063, 18385204.
22. Maskarinec G, Pagano I, Lurie G, Kolonel LN. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006, 15:732-739. 10.1158/1055-9965.EPI-05-0798, 16614116.
23. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J, Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommens J, Waggott D, Martin LJ, Scott CG, Pankratz VS, Hankinson SE, Hazra A, Hunter DJ, Hopper JL, Southey MC, Chanock SJ, Silva Idos S, Liu J, Eriksson L, Couch FJ, Stone J, Apicella C, Czene K, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 2011, 43:185-187. 10.1038/ng.760, 3076615, 21278746.
24. Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, Weaver DL, Schairer C, Taplin SH, Sherman ME. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 2012, 104:1218-1227. 10.1093/jnci/djs327, 3611814, 22911616.
25. Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011, 29:3232-3239. 10.1200/JCO.2010.31.4427, 3158597, 21768473.
26. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011, 90:605-611. 10.1038/clpt.2011.153, 21900890.
27. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012, 104:452-460. 10.1093/jnci/djs126, 3611934, 22395643.
28. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 Trial. J Natl Cancer Inst 2012, 104:441-451. 10.1093/jnci/djs125, 3309132, 22395644.
29. Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013, 31:176-180. 10.1200/JCO.2012.44.6625, 23091108.